ClinicalTrials.gg
CompletedNCT07582341Updated Oct 30, 2026

Combined Intravenous and Irrigation Tranexamic Acid During Percutaneous Nephrolithotomy

A Phase 4 interventional study of Tranexamic acid and Normal Saline in Kidney Stones, Surgical Blood Loss and Percutaneous Nephrolithotomy, sponsored by Benha University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Benha University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jun 2025, registered May 2026).
Updated Oct 30, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Kidney Calculi with a site in Egypt — 21 open to participants now, 23 under way, none of them phase 3. Kidney Calculi · Egypt.

Enrollment
32nd of 52
90 · median 100
Started
2025
with 10 others
Phase 4
2 of 57
none open now
Registered
50th of 57
by date
Lead sponsor
3 of 57
Benha University

Among the 57 studies in Kidney Calculi with a site in Egypt, this one is the 32nd largest by enrollment of the 52 interventional ones that give a count, is one of 11 that started in 2025, is one of 2 in phase 4, and was the 50th registered.

Kidney Calculi

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

Browse Kidney Calculi studies →

Open to participants now

21 of the 57 studies in Kidney Calculi with a site in Egypt are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Kidney Calculi with a site in Egypt, or all of them as a file.
02

Study summary

Percutaneous nephrolithotomy is a minimally invasive surgical procedure used to remove large kidney stones. Although it is an effective treatment, bleeding during and after the procedure remains one of the main concerns and may sometimes require blood transfusion.

Tranexamic acid is a medication that helps reduce bleeding by limiting the breakdown of blood clots. It can be given through a vein and may also be used locally in irrigation fluid during surgery. This study evaluates whether using tranexamic acid by both routes during percutaneous nephrolithotomy can reduce blood loss, improve the clarity of the surgical field during endoscopy, and reduce the need for blood transfusion.

The study included adult patients with kidney stones larger than two centimeters who were suitable for percutaneous nephrolithotomy. Patients were randomly assigned to receive either tranexamic acid through a vein and in the irrigation fluid, or normal saline as a control treatment. Blood loss was assessed using hemoglobin and hematocrit levels before and after surgery, as well as hemoglobin concentration in the irrigation fluid collected at the end of the operation. The surgeon also assessed the clarity of the surgical field using a ten-point visual scale.

The hypothesis of the study is that combined intravenous and local administration of tranexamic acid in irrigation fluid during percutaneous nephrolithotomy reduces blood loss, improves surgical visibility, and lowers the need for blood transfusion compared with normal saline.

03

Conditions studied

  • Kidney Stones
  • Surgical Blood Loss
  • Percutaneous Nephrolithotomy

Keywords

  • Kidney stones
  • Irrigation fluid
  • Blood loss
  • Blood transfusion
  • Tranexamic acid
  • Percutaneous nephrolithotomy
  • Renal stones
  • Surgical field visibility
  • Endoscopic visual clarity
  • Urologic surgery
04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18 years or older.
  • Patients with primary renal stones larger than 2 cm.
  • Patients scheduled for elective percutaneous nephrolithotomy (PCNL).

Exclusion criteria

Exclusion Criteria:

  • Morbid obesity.
  • Known renal anatomical anomalies or a solitary functioning kidney.
  • Severe hydronephrosis affecting renal parenchymal thickness.
  • Known to tranexamic acid.
  • Active coagulopathy.
  • Current anticoagulant or antiplatelet therapy.
  • History of hematological or thromboembolic disease.
  • Chronic renal or hepatic impairment.
  • Active uncontrolled urinary tract infection.
  • (ASA) physical status class III or higher.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Combined Tranexamic Acid Group

    Participants in this arm received tranexamic acid 10 milligrams per kilogram intravenously in 250 milliliters normal saline 15 minutes before induction of anesthesia, in addition to the same dose of tranexamic acid added to the first 4 liters of irrigation fluid during percutaneous nephrolithotomy.

    Drug: Tranexamic acid

  • Placebo comparator
    Normal Saline Control Group

    Participants in this arm received 250 milliliters normal saline intravenously 15 minutes before induction of anesthesia, in addition to normal saline placebo added to the first 4 liters of irrigation fluid during percutaneous nephrolithotomy.

    Drug: Normal Saline

Interventions

  • Tranexamic acid was administered as a combined intravenous and local intervention during percutaneous nephrolithotomy. The intravenous dose was given before anesthesia induction, and the local dose was added to the initial irrigation fluid used during the procedure.

  • DrugNormal Saline

    Normal saline was used as the placebo comparator. It was administered intravenously before anesthesia induction and added to the initial irrigation fluid during percutaneous nephrolithotomy.

06

What researchers measure

Primary outcomes

  1. Change in hemoglobin concentration after percutaneous nephrolithotomy

    Estimated intraoperative blood loss (mL) during percutaneous nephrolithotomy, calculated using the hemoglobin concentration measured in the collected and homogenized irrigation effluent and the total volume of collected fluid. All irrigation effluent, urethral catheter drainage, and blood clots were collected throughout the procedure, and a representative sample was analyzed for hemoglobin concentration. Lower estimated blood loss indicates less intraoperative bleeding.

    Time frame: Intraoperatively, assessed at the end of surgery.

Secondary outcomes

  1. Change in Hematocrit After Percutaneous Nephrolithotomy

    Change in hematocrit, expressed in percentage points, calculated as the difference between hematocrit measured within 24 hours before surgery and 24 hours after surgery. Negative values indicate a postoperative reduction in hematocrit.

    Time frame: Within 24 hours preoperatively and at 24 hours postoperatively.

  2. Need for blood transfusion

    Number of participants requiring blood transfusion during or after percutaneous nephrolithotomy. Transfusion requirement was recorded according to the patient's clinical condition and laboratory findings.

    Time frame: Intraoperatively and up to 24 hours postoperatively.

  3. Hemoglobin concentration in irrigation fluid

    Hemoglobin concentration measured in the irrigation fluid collected at the end of surgery as an estimate of intraoperative blood loss.

    Time frame: At the end of surgery

  4. Intraoperative Endoscopic Surgical Field Visibility Score

    Endoscopic surgical field visibility was assessed by the operating surgeon at the end of percutaneous nephrolithotomy using a subjective 10-point numerical rating scale representing overall visualization throughout the procedure. Scores range from 1 (worst visibility) to 10 (best attainable visibility), with higher scores indicating better surgical field clarity. The scale has not been formally validated for percutaneous nephrolithotomy.

    Time frame: At the end of surgery

  5. Postoperative Hematuria

    Number of participants who developed visible blood-stained urine after percutaneous nephrolithotomy.

    Time frame: Up to 24 hours postoperatively

  6. Number of Participants Requiring Additional Hemostatic Intervention

    Number of participants requiring additional therapeutic or procedural intervention to control bleeding during or after percutaneous nephrolithotomy, beyond routine intraoperative hemostatic measures. Additional interventions were recorded according to the clinical and surgical documentation.

    Time frame: Intraoperatively and up to 24 hours postoperatively.

  7. Number of Participants With Postoperative Infection

    Number of participants who developed postoperative infection after percutaneous nephrolithotomy.

    Time frame: Up to 24 hours postoperatively

  8. Postoperative Hematuria

    Number of participants with visible hematuria requiring continued nephrostomy tube closure or delayed nephrostomy tube removal.

    Time frame: Up to 24 hours postoperatively

  9. Change in Hemoglobin Concentration

    Change in Hemoglobin Concentration After Percutaneous Nephrolithotomy Description: Change in blood hemoglobin concentration (g/dL), calculated as the difference between hemoglobin measured within 24 hours before surgery and 24 hours after surgery. Negative values indicate a postoperative reduction in hemoglobin concentration.

    Time frame: Within 24 hours preoperatively and at 24 hours postoperatively.

  10. Total Intraoperative Irrigation Fluid Volume

    Total volume of irrigation fluid used during percutaneous nephrolithotomy, measured in liters (L). Irrigation volume was recorded throughout the procedure for each participant.

    Time frame: Intraoperatively, assessed at the end of surgery.

  11. Number of Participants With Residual Renal Stones Following Percutaneous Nephrolithotomy

    Number of participants with residual renal stones identified during postoperative assessment following percutaneous nephrolithotomy. Residual stone status and the requirement for subsequent stone-management procedures were recorded.

    Time frame: 24 hours postoperatively

  12. Postoperative Length of Hospital Stay

    Duration of postoperative hospitalization, measured in days from the date of percutaneous nephrolithotomy to hospital discharge.

    Time frame: From the day of surgery until hospital discharge (postoperative days 1-3).

  13. Postoperative Fever

    Number of participants who developed documented postoperative fever following percutaneous nephrolithotomy, based on postoperative temperature monitoring and clinical records. Fever was recorded separately from confirmed postoperative infection.

    Time frame: From completion of surgery through 24 hours postoperatively

07

Study locations

1 site
  • Benha University Hospital
    Banhā, Qalyubia Governorate 13511, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual participant data related to the study outcomes will be available for sharing. The shared data may include baseline characteristics, operative data, hemoglobin and hematocrit measurements, blood transfusion data, irrigation fluid hemoglobin concentration, surgical field visibility score, and recorded postoperative outcomes.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will become available beginning 6 months after publication of the study results and will remain available for 2 years.

Access criteria: Data will be available upon reasonable request from qualified researchers for scientific purposes. Requests will be reviewed by the study investigators, and data will be shared after approval and completion of a data use agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2025 to primary completion in Feb 2026, 7 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start May 2025 → Jun 2025, primary completion Apr 2026 → Feb 2026 and completion Apr 2026 → Feb 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 12, 2026
StartActual
Jun 30, 2025was May 2025
Primary completionActual
Feb 15, 2026was Apr 2026
CompletionActual
Feb 15, 2026was Apr 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 30, 2025→Jun 30, 2025
Oct 30, 2026
Primary completion
Apr 15, 2026→Feb 15, 2026
Oct 30, 2026
Study completion
Apr 15, 2026→Feb 15, 2026
Oct 30, 2026
Eligibility
Maximum age 70 Years→none; 3 inclusion criteria edited, 2 removed; 7 exclusion criteria edited, 2 added, 3 removed
What changed in the criteria
Inclusion criteria
  • EditedAdult patients aged 18 to 70 yearsyears or older.
  • EditedPatients with primary renal stones larger than 2 centimeterscm.
  • EditedPatients scheduled for elective percutaneous nephrolithotomy (PCNL).
  • RemovedNormal renal function, defined as serum creatinine less than or equal to 1.5 milligrams per deciliter.
  • RemovedAmerican Society of Anesthesiologists physical status class 1 or 2.
Exclusion criteria
  • EditedSolitaryKnown renal anatomical anomalies or a solitary functioning kidney.
  • RemovedDecompensated coagulopathy or known hematological disease.
  • AddedSevere hydronephrosis affecting renal parenchymal thickness.
  • EditedHypersensitivityKnown hypersensitivity to tranexamic acid.
  • ChangedBefore Pregnancy.Now Active coagulopathy.
  • EditedCurrent anticoagulationanticoagulant or antiplatelet therapy.
  • EditedHistory of cerebrovascular eventshematological or thromboembolismthromboembolic disease.
  • RemovedUncontrolled arrhythmia.
  • EditedAcuteChronic renal or chronic renal diseasehepatic impairment.
  • EditedUntreatedActive uncontrolled urinary tract infection or urosepsis.
  • RemovedRenal anatomical anomalies, including ectopic kidney, duplex collecting system, or horseshoe kidney.
  • AddedAmerican Society of Anesthesiologists (ASA) physical status class III or higher.
Oct 30, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameChange in hemoglobin concentration after percutaneous nephrolithotomyPreoperative, immediate postoperative, and 24 hours postoperative → Intraoperatively, assessed at the end of surgery.
  • DescriptionChange in hemoglobin concentration after percutaneous nephrolithotomy: how it is measured was reworded
Oct 30, 2026
Secondary outcomes
4 edited, 1 time frame changed, 5 added, 1 description edited
What changed in the outcomes
  • EditedChange in hematocrit concentration after percutaneous nephrolithotomyHematocrit After Percutaneous NephrolithotomyTime frame: Preoperative, immediate postoperative, and 24 hours postoperative → Within 24 hours preoperatively and at 24 hours postoperatively.
  • EditedIntraoperative Endoscopic surgical field visibility scoreSurgical Field Visibility ScoreTime frame: At the end of surgery
  • EditedNeed forNumber of Participants Requiring Additional Hemostatic InterventionTime frame: Up to 24 hours postoperatively → Intraoperatively and up to 24 hours postoperatively.
  • EditedNumber of Participants With Postoperative InfectionTime frame: Up to 24 hours postoperatively
  • AddedChange in Hemoglobin ConcentrationTime frame: Within 24 hours preoperatively and at 24 hours postoperatively.
  • AddedTotal Intraoperative Irrigation Fluid VolumeTime frame: Intraoperatively, assessed at the end of surgery.
  • AddedNumber of Participants With Residual Renal Stones Following Percutaneous NephrolithotomyTime frame: 24 hours postoperatively
  • AddedPostoperative Length of Hospital StayTime frame: From the day of surgery until hospital discharge (postoperative days 1-3).
  • AddedPostoperative FeverTime frame: From completion of surgery through 24 hours postoperatively
  • Time frameNeed for blood transfusionIntraoperatively and up to 24 hours postoperatively → Intraoperatively and up to 24 hours postoperatively.
  • DescriptionNeed for blood transfusion: how it is measured was reworded
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Start date May 30, 2025→Jun 30, 2025
    Primary completion Apr 15, 2026→Feb 15, 2026
    Study completion Apr 15, 2026→Feb 15, 2026
    Eligibility Maximum age 70 Years→none; 3 inclusion criteria edited, 2 removed; 7 exclusion criteria edited, 2 added, 3 removed
    What changed in the criteria
    Inclusion criteria
    • EditedAdult patients aged 18 to 70 yearsyears or older.
    • EditedPatients with primary renal stones larger than 2 centimeterscm.
    • EditedPatients scheduled for elective percutaneous nephrolithotomy (PCNL).
    • RemovedNormal renal function, defined as serum creatinine less than or equal to 1.5 milligrams per deciliter.
    • RemovedAmerican Society of Anesthesiologists physical status class 1 or 2.
    Exclusion criteria
    • EditedSolitaryKnown renal anatomical anomalies or a solitary functioning kidney.
    • RemovedDecompensated coagulopathy or known hematological disease.
    • AddedSevere hydronephrosis affecting renal parenchymal thickness.
    • EditedHypersensitivityKnown hypersensitivity to tranexamic acid.
    • ChangedBefore Pregnancy.Now Active coagulopathy.
    • EditedCurrent anticoagulationanticoagulant or antiplatelet therapy.
    • EditedHistory of cerebrovascular eventshematological or thromboembolismthromboembolic disease.
    • RemovedUncontrolled arrhythmia.
    • EditedAcuteChronic renal or chronic renal diseasehepatic impairment.
    • EditedUntreatedActive uncontrolled urinary tract infection or urosepsis.
    • RemovedRenal anatomical anomalies, including ectopic kidney, duplex collecting system, or horseshoe kidney.
    • AddedAmerican Society of Anesthesiologists (ASA) physical status class III or higher.
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameChange in hemoglobin concentration after percutaneous nephrolithotomyPreoperative, immediate postoperative, and 24 hours postoperative → Intraoperatively, assessed at the end of surgery.
    • DescriptionChange in hemoglobin concentration after percutaneous nephrolithotomy: how it is measured was reworded
    Secondary outcomes 4 edited, 1 time frame changed, 5 added, 1 description edited
    What changed in the outcomes
    • EditedChange in hematocrit concentration after percutaneous nephrolithotomyHematocrit After Percutaneous NephrolithotomyTime frame: Preoperative, immediate postoperative, and 24 hours postoperative → Within 24 hours preoperatively and at 24 hours postoperatively.
    • EditedIntraoperative Endoscopic surgical field visibility scoreSurgical Field Visibility ScoreTime frame: At the end of surgery
    • EditedNeed forNumber of Participants Requiring Additional Hemostatic InterventionTime frame: Up to 24 hours postoperatively → Intraoperatively and up to 24 hours postoperatively.
    • EditedNumber of Participants With Postoperative InfectionTime frame: Up to 24 hours postoperatively
    • AddedChange in Hemoglobin ConcentrationTime frame: Within 24 hours preoperatively and at 24 hours postoperatively.
    • AddedTotal Intraoperative Irrigation Fluid VolumeTime frame: Intraoperatively, assessed at the end of surgery.
    • AddedNumber of Participants With Residual Renal Stones Following Percutaneous NephrolithotomyTime frame: 24 hours postoperatively
    • AddedPostoperative Length of Hospital StayTime frame: From the day of surgery until hospital discharge (postoperative days 1-3).
    • AddedPostoperative FeverTime frame: From completion of surgery through 24 hours postoperatively
    • Time frameNeed for blood transfusionIntraoperatively and up to 24 hours postoperatively → Intraoperatively and up to 24 hours postoperatively.
    • DescriptionNeed for blood transfusion: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07582341
Lead sponsor
Benha University
Responsible party
Hossam Hassan Mohamed Mandour (Resident of Urology, Benha University) — Principal investigator
First posted
May 12, 2026
Start date
Jun 30, 2025
Primary completion
Feb 15, 2026
Completion
Feb 15, 2026
Last update
Oct 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion